Navigation Links
Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
Date:9/10/2008

OXFORD, England, September 10 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients.

Circassia conducted the double-blind study in Germany, where patients with a confirmed history of cat allergies received a single dose of ToleroMune therapy or placebo. The 88 study participants were divided into groups, with each receiving a different dose, either via subcutaneous or intradermal injection to compare the two routes of administration. To test the effect of the treatment, patients received a microscopic dose of cat dander (the main allergen responsible for cat allergies) into their skin several weeks later. Patients who received ToleroMune therapy via the most effective administration route had markedly reduced skin reactions to the cat allergen at all of the five dose levels tested compared with placebo. The most effective dose reduced reactions by over 40%, compared with 10% for placebo. Throughout the study the ToleroMune treatment proved well tolerated, with no serious or severe adverse events experienced in any of the groups, despite the steadily increasing doses.

"These results are extremely encouraging, both for Circassia and the huge number of people who suffer from allergies. Current treatment options address the symptoms only or require repeated administrations over many months under specialist supervision because of the potential for serious and even life-threatening side effects, which is a particularly important issue for cat allergy therapies. Therefore, achieving a marked reduction in allergic responses after just a single dose is remarkable, and we a
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
2. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
3. TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
4. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
5. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
6. CureDMs Diabetes Therapy Achieves Major Development Milestone
7. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
8. Bionomics Achieves US$1 Million Milestone Payment from Genmab
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Roche under the trade name ... in the world. In Feb.26, 2010, it was approved ... injections available in China all ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final recognition ... Contact Lens Health Week, 1-800 Contacts is sharing how ... that contact lens wearers who do not properly care ... for eye infections. Most contact lens ... but a clean lens case is sometimes overlooked.  When ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... S.C., April 12, 2011 Southern Home Medical ... healthcare services, healthcare professionals and equipment to medical ... results from operations for fiscal year 2010 have ... from Encore Medical Staffing. In a ...
... ST. PAUL, Minn., April 12, 2011 According to ... safety edit, designed to require provider prior authorization (PA) ... use of insulin or nitrate (CIN), potentially decreased members, ... at the Academy of Managed Care Pharmacy,s 23rd Annual ...
Cached Medicine Technology:Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2Point-of-Sale Electronic Safety Check May Reduce Heart Attack Risk for Diabetic Patients 2
(Date:8/30/2015)... , ... August 30, 2015 , ... ... (HIFU) medical devices for the treatment of prostate cancer, has announced the roll-out ... summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire ... heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine ... experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models ... the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... , , TAMPA, Fla., July 23 ... scrubs and chemical drugs and armed himself with a movie ... due to preventable illness, Burton found an alarming connection between ... of death. Now he,s going to tell the world what ...
... recent years. This is fact, but what is not clear ... have shown that family conflict is not a significant factor. ... striking: in Spain, 24% of women take antidepressants and more ... is often related to family or work-related problems. We wanted ...
... Ind., July 23 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) ... 2009. You are invited to participate in a webcast the following ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Third Quarter ... the public after the NYSE close on Thursday, August 6, 2009. ...
... YORK, July 23 The U.S. Fund for UNICEF announced today ... UNICEF,s mission to save, protect and improve the lives of children ... reducing the number of preventable deaths of children, from 25,000 per ... will lead the steering committee and host UNICEF,s Next Generation launch ...
... July 23 At the 2009 American Association of ... Anaheim, California, Elekta will demonstrate how the company,s comprehensive ... cancer care with precision and ease. , , ... deliver radiation treatments, Elekta booth 423 will highlight treatment ...
... , WARREN, N.J., July 23 MonoSol Rx, the ... dissolving thin film pharmaceutical products, today announced the appointment of Theodore ... will report to Keith J. Kendall, Executive Vice President and CFO. ... are pleased to welcome Ted to MonoSol Rx and look forward ...
Cached Medicine News:Health News:Nurse Turned Filmmaker Makes Lifesaving Film 2Health News:Almost 1 quarter of Spanish women take antidepressants 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast 2Health News:U.S. Fund for UNICEF and Jenna Bush Hager Announce Next Generation Initiative to Improve Lives of Children Around the World 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 3Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 2Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 3
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
Medicine Products: